The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

• Published in: Supportive care in cancer Vol. 25; no. 8; pp. 2619 - 2629
• Main Authors: Lyman, Gary H., Allcott, Kim, Garcia, Jacob, Stryker, Scott, Li, Yanli, Reiner, Maureen T., Weycker, Derek
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2017; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Cancer; Chemotherapy; Comparative analysis; Drug therapy; Effectiveness; Evidence-based medicine; Female; Granulocyte Colony-Stimulating Factor - therapeutic use; Granulocytes; Humans; Induction Chemotherapy - methods; Male; Medicine; Medicine & Public Health; Middle Aged; Neutropenia; Neutropenia - chemically induced; Neutropenia - drug therapy; Nursing; Nursing Research; Oncology; Pain Medicine; Prospective Studies; Rehabilitation Medicine; Review Article; Systematic review; Pegfilgrastim; Granulocyte colony-stimulating factor; Filgrastim; Neutropenia
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-017-3703-y

Purpose Granulocyte colony-stimulating factors (G-CSF) are commonly used in clinical practice to prevent febrile neutropenia (FN). US and EU prescribing information and treatment guidelines from the NCCN, ASCO, and EORTC specify that pegfilgrastim, a long-acting (LA) G-CSF, should be administered at least 24 h after myelosuppressive chemotherapy. Nevertheless, many patients receive LA G-CSFs on the same day as chemotherapy. This systematic literature review evaluated the relative merits of same-day versus next-day dosing of LA G-CSFs. Methods A broad Ovid MEDLINE® and Embase® literature search was conducted that examined all publications indexed before May 9, 2016 that compared same-day versus next-day LA G-CSF administration. A congress abstract literature search included congresses from January 1, 2011 to April 6, 2016. The parameters for this review were prospectively delineated in a research protocol and adhered to the PRISMA Guidelines. Results The first part of the systematic literature search identified 1736 publications. After elimination of duplicates, title/abstract screening was conducted on 1440 records, and full text review was conducted on 449 publications. Eleven publications met all criteria and are included in this systematic review; of these, four included data from randomized or single arm prospective studies, and seven were retrospective studies. In most studies included in this review and across a variety of tumor types, administration of pegfilgrastim at least 24 h after myelosuppressive chemotherapy resulted in improved patient outcomes. Conclusions Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy.